Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05820100 · ClinicalTrials.gov registry record
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
A clinical trial of Retinitis Pigmentosa and Retinal Dystrophy, sponsored by Nanoscope Therapeutics.
- Completed
- Registry status
- 35
- Enrollment target
- 8
- Study locations
NCT05820100: Completed study of Retinitis Pigmentosa and Retinal Dystrophy, sponsored by Nanoscope Therapeutics.
NCT05820100 is a study of Retinitis Pigmentosa and Retinal Dystrophy that has completed, run by Nanoscope Therapeutics. The registered enrollment target is 35 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05820100, a study of Retinitis Pigmentosa and Retinal Dystrophy, has completed, sponsored by Nanoscope Therapeutics.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.
Primary Outcome
A higher MLYMT score (range -1 to 5) indicates better navigational vision.
Conditions Studied
Interventions
- OTHER Observational
Study Locations (8)
Texas
- Nanoscope Clinical Site - Bellaire
- Nanoscope Clinical Site - McAllen
- Nanoscope Clincal Site - San Antonio
Arizona
- Nanoscope Clinical Site - Phoenix
California
- Nanoscope Clinical Site - Beverly Hills
Florida
- Nanoscope Clinical Site - Miami
North Dakota
- Nanoscope Clinical Site - Fargo
Other
- Nanoscope Clinical Site - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2023-10-17 |
What the finished NCT05820100 record still lists
NCT05820100 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT05820100 lists 8 locations in 6 states (Texas, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT05820100 about?
NCT05820100 is a clinical study titled "Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT". This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a c...
What is the current status of trial NCT05820100?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2023-04-25. Estimated completion is 2023-10-17.
What conditions does trial NCT05820100 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Retinal Dystrophy.
What interventions are being tested in trial NCT05820100?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT05820100?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05820100 being conducted?
This trial has 8 study locations across Arizona, California, Florida, North Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05820100's enrollment target sits among peer trials
35 19th of 37 higher than 19 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI